pwshub.com

A 10-Day Test Is Coming for Bond Market Battered by Selloff

(Bloomberg) -- The US bond market, already stung by the worst selloff in six months, now heads into a crucial two-week stretch that will likely chart its course for the rest of the year.

Most Read from Bloomberg

A series of market-moving events are coming in rapid succession, kicked off by the Treasury Department’s announcement Wednesday on the scale of its coming debt sales and by monthly payroll figures Friday that will show whether the economy is cooling enough to justify further interest-rate cuts.

That’s followed by even bigger ones next week: The Nov. 5 presidential election and, two days later, the Federal Reserve’s first meeting since it began easing monetary policy in September.

“The risk really for the next few weeks is elevated,” said Alex Chaloff, chief investment officer at Bernstein Private Wealth Management.

Treasury prices have tumbled sharply over the past month as the continued strength of the economy casts doubt on how deeply the Fed will cut interest rates in the months ahead. The presidential election has added to the uncertainty, with some investors speculating that a victory by Donald Trump will push yields higher on anticipation that his tax cuts and tariffs would fan inflation pressures and keep rates elevated.

While the Fed started easing last month with a half-percentage-point move, traders jettisoned once-widespread forecasts that it would continue to cut swiftly after data signaled the economy is expanding at a relatively rapid pace. As a result, yields have jumped sharply, pushing up borrowing costs across markets and sending Treasuries toward the first monthly loss since April.

“It’s been such a momentous cycle so far — and a lot can happen in the next two weeks,” said Sinead Colton Grant, chief investment officer at BNY Wealth.

That run of key news events is raising a risk that the selloff could gather some steam in the next few weeks, particular as investors position for fallout from the US election. In one sign of that, traders are paying the highest premiums this year for options that seek to protect portfolios against yield spikes.

Yet some of the upcoming events may also be supportive of the bond market. The Treasury Department is expected announce that it’s keeping the size of its debt auctions steady in the upcoming quarter — averting any supply pressures — though traders will also be paying close attention to any signals on the future trajectory.

Source: finance.yahoo.com

Related stories
1 week ago - Stocks are upbeat as Nvidia ht a fresh record high, with the next batch of big bank earnings in focus.
1 month ago - After a typical skittish first-day reaction, world markets are on Thursday embracing the new Federal Reserve stance as insurance on the holy grail of a soft economic landing. Fed boss Jerome Powell described Wednesday's outsize...
1 month ago - (Bloomberg) -- European stocks face a series of hurdles to extend their 2024 rally after hitting another record high this week.Most Read from BloombergVanderbilt Leases Struggling NYC Seminary for Campus ExpansionClimate Migrants Stand to...
1 month ago - One ETF presents a lot of the same benefits as the other, with much less dependence on a few companies.
1 month ago - A short pep talk I delivered to kick off a Three-Day Startup challenge event. And overwhelming confirmation that the lesson is correct.
Other stories
17 minutes ago - Investors would probably love to hear a more decisive view. But predicting long-term returns is hard, and these kinds of imprecise assessments are the best we can do as we manage our expectations.
17 minutes ago - Want to add reliable dividend payers to your portfolio? These household names can deliver inflation-beating payouts for many years to come.
1 hour ago - Plans to shut down a vital terminal in the North Sea have sparked a bitter legal row over claims it will damage the UK’s oil and gas production.
2 hours ago - Oklo's stock has surged as investors look to nuclear energy stocks as the next big AI trade. But the company and its competitors face several regulatory and supply-chain hurdles.
3 hours ago - Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.